Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

BACKGROUND: This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib. METHODS: Data were from two phase 3 studies, OPAL Broaden (12 months) and OPAL Beyond (6 months). Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, Dafna D., Coates, Laura C., Wu, Joseph, Fallon, Lara, Bacci, Elizabeth D., Cappelleri, Joseph C., Bushmakin, Andrew G., Helliwell, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826651/
https://www.ncbi.nlm.nih.gov/pubmed/35139908
http://dx.doi.org/10.1186/s13075-022-02721-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826651/
https://www.ncbi.nlm.nih.gov/pubmed/35139908
http://dx.doi.org/10.1186/s13075-022-02721-0

Ejemplares similares